Celgene Corporation (CELG), Novartis AG (ADR) (NVS): Momenta Pharmaceuticals, Inc. (MNTA) Earnings Remind Investors of Growing Pains

The company’s novel oncology compound, M402, is being evaluated with Abraxane from Celgene Corporation (NASDAQ:CELG) and gemcitabine from Eli Lilly in early stage trials in patients with pancreatic cancer. It would be big news for Momenta, but the combination therapy could generate a revenue stream for Celgene Corporation (NASDAQ:CELG) as well. The drug has a long way to go, but safety and dosing data should be released in the first half of 2014. That would give investors at least three major stock-moving catalysts (combined with the launch of generic Copaxone and biosimilar updates) to look forward to next year.

Foolish bottom line
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is a very interesting company that has the potential to create an amazing amount of value in the pharmaceutical industry. The disruptive platform for identifying, developing, and manufacturing generic and novel products has much left to prove, but long-term investors could certainly have a gem in their portfolio a few years from now if several of the company’s programs progress through commercialization. I will certainly look to add shares to my personal portfolio before the end of the year. Will you be joining me?

The article Momenta Earnings Remind Investors of Growing Pains originally appeared on Fool.com and is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.